Arab Board Oncology Clinical Practice Questions - Arab Board Medical Oncology Final Practical Clinical Examination - الامتحان النهائي العملي لاختصاص طب الأورام (ABHS) Exam

Access More Questions

A 45-year-old premenopausal woman with clinical stage IIA (cT2N0M0) HER2-positive (IHC 3+), ER-negative breast cancer completes 6 cycles of neoadjuvant TCHP (docetaxel, carboplatin, trastuzumab, and pertuzumab). She undergoes breast-conserving surgery, and final surgical pathology reveals a 1.2 cm residual invasive carcinoma in the breast with negative margins and clear lymph nodes (ypT1c ypN0). What is the preferred adjuvant HER2-targeted therapy?

Trastuzumab emtansine (T-DM1) for 14 cycles Trastuzumab plus pertuzumab to complete 1 full year Trastuzumab monotherapy to complete 1 full year Trastuzumab deruxtecan (T-DXd) for 8 cycles

Correct Answer:

Trastuzumab emtansine (T-DM1) for 14 cycles

Access more questions from this quiz

Continue to Arab Board Oncology Clinical Practice Questions - Arab Board Medical Oncology Final Practical Clinical Examination - الامتحان النهائي العملي لاختصاص طب الأورام (ABHS) Exam for more practice questions and the full quiz experience.

Access More Questions